CRISPR Therapeutics AG
CRSPNext catalyst
CTX001
Beta-Thalassemia
Get an email about CRSP's next catalysts
Track CRISPR Therapeutics (CRSP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CRSP Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.06 | FQ end Sep/2026 | Call: tbd
CTX001 Phase 3 Est. Readout
Estimated primary completion for CTX001 trial (NCT05329649) in Sickle Cell Disease. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
WebsiteClear Cell Renal Cell Carcinoma
1 drug in this indication
B-cell Lymphoma
1 drug in this indication
ANGPTL3 editing for triglyceride and LDL lowering
1 drug in this indication
ANGPTL3 targeting
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CRISPR Therapeutics AG's drug pipeline?→
CatalystAlert tracks 5 drug candidates in CRISPR Therapeutics AG's (CRSP) pipeline across Phase 3, Phase 2. Its lead program is CTX001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CRISPR Therapeutics AG's next FDA catalyst?→
CRISPR Therapeutics AG's (CRSP) next tracked catalyst is a Phase 3 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRSP biotech catalysts?→
Add CRSP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CRISPR Therapeutics AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.